Regor’s Obesity Pill RGT-075 Shows Moderate Weight Loss in Phase 2a, Advances to Phase 2b Trial

Phase 2a Results:
Regor Therapeutics Group announced that its oral GLP-1 receptor agonist, RGT-075, achieved a 5% placebo-adjusted weight loss in a 12-week Phase 2a trial with no plateau in weight loss observed1.

Tolerability:
The study reported no treatment-related severe adverse events, with a 4% discontinuation rate due to adverse events, which was the same as the placebo group1.

Phase 2b Trial:
Regor initiated the COMO-1 Phase 2b dose-finding trial for RGT-075, which will evaluate multiple doses up to 225 mg over 36 weeks compared with placebo in adult patients with obesity or overweight with weight-related comorbidities1.

Clinical Significance:
RGT-075 demonstrated robust and clinically meaningful efficacy in HbA1c and systolic and diastolic blood pressure, suggesting potential benefits beyond weight loss1.

Future Plans:
Topline data from the Phase 2b study are expected at the end of 2025, with plans to explore higher doses and combination approaches in future studies1.

Sources:

1. https://www.biospace.com/press-releases/regor-releases-phase-2a-topline-results-for-rgt-075-an-oral-once-daily-small-molecule-glp-1r-agonist-and-begins-phase-2b-study-in-the-us-for-the-treatment-of-obesity